Theranostics

Scope & Guideline

Pioneering Multidisciplinary Approaches in Healthcare.

Introduction

Immerse yourself in the scholarly insights of Theranostics with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1838-7640
PublisherIVYSPRING INT PUBL
Support Open AccessYes
CountryAustralia
TypeJournal
Convergefrom 2012 to 2024
AbbreviationTHERANOSTICS / Theranostics
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA

Aims and Scopes

The journal 'Theranostics' focuses on the intersection of therapeutic and diagnostic strategies, emphasizing the development of personalized medicine and innovative technologies for disease management. It aims to bridge the gap between basic research and clinical application, fostering advancements in drug delivery systems, imaging techniques, and biomarker discovery.
  1. Theranostic Applications:
    The journal emphasizes the development and application of theranostic agents that simultaneously diagnose and treat diseases, particularly in oncology. This includes the use of nanoparticles, radioligands, and imaging agents that provide real-time monitoring of therapeutic responses.
  2. Nanomedicine and Drug Delivery:
    A significant focus is on nanotechnology and its applications in drug delivery systems. This encompasses the design of nanoparticles and nanocarriers that enhance the bioavailability and efficacy of therapeutics, especially for cancer treatment.
  3. Biomarkers and Personalized Medicine:
    The journal highlights the discovery and validation of biomarkers that can predict treatment responses and disease progression. This is crucial for the development of personalized therapeutic strategies tailored to individual patient profiles.
  4. Extracellular Vesicles and Cell Communication:
    Research on extracellular vesicles (EVs) is prominent, exploring their roles in intercellular communication, immune modulation, and as vehicles for drug delivery. EVs are studied for their potential in regenerative medicine and cancer therapy.
  5. Immunotherapy and Immune Modulation:
    The journal explores the mechanisms and applications of immunotherapy, focusing on strategies that enhance the immune response against tumors. This includes the development of immune checkpoint inhibitors and engineered immune cells.
  6. Advanced Imaging Techniques:
    Innovative imaging modalities, such as molecular imaging and ultrasound-guided techniques, are investigated for their role in enhancing the precision of diagnostics and monitoring therapeutic outcomes.
Recent trends in 'Theranostics' indicate a dynamic evolution of research themes, reflecting the growing integration of technology, personalized medicine, and innovative therapeutic strategies.
  1. Integration of Artificial Intelligence:
    The application of artificial intelligence (AI) in diagnostics and therapeutics is gaining traction, enabling more accurate predictions of treatment outcomes and improving the design of personalized therapies.
  2. Targeted and Combination Therapies:
    There is an increasing focus on targeted therapies that combine multiple modalities, such as immunotherapy with chemotherapy or radiotherapy, to enhance treatment efficacy and overcome resistance.
  3. Microbiome Research and Its Therapeutic Implications:
    Research exploring the gut microbiome's role in health and disease is emerging, particularly its influence on cancer therapy responses and overall patient outcomes.
  4. Regenerative Medicine and Stem Cell Applications:
    The use of stem cells and their derivatives for regenerative medicine is becoming a prominent theme, particularly in the context of tissue repair and treatment of degenerative diseases.
  5. Biomaterials and Smart Drug Delivery Systems:
    Innovative biomaterials designed for controlled and targeted drug delivery are trending, with a focus on enhancing therapeutic efficacy while minimizing side effects.
  6. Extracellular Vesicle Therapeutics:
    The therapeutic potential of extracellular vesicles, including their use as drug delivery vehicles and biomarkers, is rapidly expanding, indicating a shift towards utilizing natural cellular components for therapeutic applications.

Declining or Waning

While 'Theranostics' maintains a robust focus on emerging therapeutics and diagnostics, some themes have seen a decline in prominence over recent years, reflecting shifts in research priorities and technological advancements.
  1. Conventional Chemotherapy Approaches:
    There is a noticeable decline in publications centered on traditional chemotherapy methods without the integration of novel delivery systems or biomarkers. This shift suggests a move towards more targeted and personalized treatment modalities.
  2. Basic Laboratory Studies Without Clinical Relevance:
    Research that lacks direct implications for clinical application or translational potential is less frequently published, as the journal increasingly prioritizes studies that bridge laboratory findings with clinical outcomes.
  3. Non-targeted Drug Development:
    There is a waning interest in non-targeted approaches to drug development, as the field moves towards more precise and targeted therapies that consider individual patient characteristics and tumor heterogeneity.
  4. Non-immunotherapeutic Strategies:
    While immunotherapy continues to rise, publications focused solely on non-immunotherapeutic strategies without considering immune interactions or responses are becoming less common.

Similar Journals

CANCER GENE THERAPY

Innovating Genetic Solutions for Oncology
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

Elevating knowledge in therapeutic drug systems.
Publisher: BEGELL HOUSE INCISSN: 0743-4863Frequency: 6 issues/year

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

Cancer Discovery

Fostering Dialogue to Revolutionize Cancer Research
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.

VIEW

Uniting Global Scholars in Biomedical Engineering Advancement.
Publisher: WILEYISSN: 2688-3988Frequency: 6 issues/year

VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

Molecular Therapy Oncolytics

Exploring the Frontiers of Molecular Medicine in Oncology
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

CYTOKINE & GROWTH FACTOR REVIEWS

Catalyzing Innovation in Cytokine and Growth Factor Biology
Publisher: ELSEVIER SCI LTDISSN: 1359-6101Frequency: 6 issues/year

CYTOKINE & GROWTH FACTOR REVIEWS, published by Elsevier Science Ltd, serves as a premier platform for the dissemination of cutting-edge research in the fields of Biochemistry, Genetics and Molecular Biology, Endocrinology, and Immunology. With an impressive impact factor that places it in the Q1 category across multiple disciplines, the journal brings together high-quality reviews that critically evaluate recent advances in cytokine and growth factor biology. This ensures that researchers and professionals have access to valuable insights that enhance current knowledge and stimulate further investigation. Although it is not an open-access journal, its rigorous selection process and high ranking – including Rank #7 in Medicine: Endocrinology, Diabetes and Metabolism – underscore its significance within the scientific community. With its converged years of publication from 1996 to 2024, CYTOKINE & GROWTH FACTOR REVIEWS remains a crucial resource for students, researchers, and professionals alike, informing their work with comprehensive overviews of key topics in the dynamic interplay of growth factors and cytokines.

INTERNATIONAL JOURNAL OF ONCOLOGY

Advancing cancer research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Nanomedicine-Nanotechnology Biology and Medicine

Connecting Nanoscience and Medicine for Revolutionary Outcomes
Publisher: ELSEVIERISSN: 1549-9634Frequency: 6 issues/year

Nanomedicine-Nanotechnology Biology and Medicine is a leading journal published by Elsevier, dedicated to the exploration of innovative applications of nanotechnology in the fields of biology and medicine. With an ISSN of 1549-9634 and an E-ISSN of 1549-9642, this esteemed journal provides a platform for high-quality research, comprehensively covering areas including bioengineering, biomedical engineering, pharmaceutical science, and nanoscience. Notably, it holds a significant position in various categories with a Q2 ranking in multiple disciplines and a prestigious Q1 ranking in Pharmaceutical Science, emphasizing its impact within the scientific community. By facilitating access to cutting-edge studies and advancements, Nanomedicine-Nanotechnology Biology and Medicine serves as an essential resource for researchers, professionals, and students alike, contributing significantly to the ongoing development of nanomedicine and its pivotal role in improving healthcare outcomes. The journal operates without open access; however, it remains committed to disseminating valuable knowledge to a global audience.

International Journal of Nanomedicine

Empowering researchers to redefine the landscape of medicine.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2013Frequency: 1 issue/year

International Journal of Nanomedicine, published by DOVE MEDICAL PRESS LTD, is a leading open access journal dedicated to advancing the field of nanomedicine and its applications in healthcare. Since its establishment in 2006, the journal has grown significantly, now encompassing a wide array of topics including bioengineering, biomaterials, biophysics, drug discovery, and pharmaceutical sciences, and is recognized in Q1 quartiles across major categories like *Nanoscience and Nanotechnology* and *Organic Chemistry*. The journal boasts an impressive standing within the Scopus rankings, with high percentiles across various related fields, making it an invaluable resource for researchers, professionals, and students seeking to stay informed on the latest innovations and developments in nanomedicine. With its commitment to fostering an accessible and collaborative academic environment, the International Journal of Nanomedicine serves as a vital platform for disseminating transformative research that impacts scientific practice and healthcare outcomes globally.

Biomarker Research

Pioneering research for transformative diagnostics and therapeutics.
Publisher: BMCISSN: Frequency: 1 issue/year

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.